Navigation Links
BioMarin Appoints Dr. Gordon Vehar, Vice President of Research
Date:1/28/2008

NOVATO, Calif., Jan. 28 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today the appointment of Dr. Gordon Vehar as Vice President of Research. Former Vice President of Research and Development for Raven Biotechnologies, Dr. Vehar is the inventor of numerous biotechnology patents and the recipient of a collection of prestigious scientific awards including two Distinguished Inventor of the Year Awards from Intellectual Property Owners, Inc.

"We are very pleased to welcome Dr. Vehar to BioMarin. He brings with him extraordinary research and drug development experience and his contributions will substantially bolster our efforts to grow our early pipeline at BioMarin," said Dr. Emil Kakkis, Senior Vice President and Chief Medical Officer.

Dr. Vehar also served in various roles throughout a 20-year tenure with Genentech, including Director of Cardiovascular Research and Staff Scientist for Cardiovascular Research and Protein Chemistry. Also at Genentech, he served as Project Team Leader on various drug discovery and development projects, which yielded four marketed products. He is the recipient of the Murray Thelin Award for Outstanding Research presented by the National Hemophilia Foundation, the Inventor of the Year Award given by Intellectual Property Owners, Inc., for the human tissue plasminogen activator (t-PA) patent for the treatment of heart attacks and stroke, and the Distinguished Inventor of the Year Award from Intellectual Property Owners, Inc. for the patent on recombinant Factor VIII, a genetically engineered clotting factor enabling production of a therapeutic product for treating hemophilia A. Dr. Vehar has served on the Scientific Advisory Board for the Oklahoma Center for Molecular Medicine, he is an inventor with 37 issued patents and is the author of more than 35 publications. Dr. Vehar received a Ph.D. from the University of Cincinnati Medical School.

Dr. Vehar joins two other new
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
2. BioMarin and IGAN Biosciences to Collaborate on Development of an Enzyme Therapy to Treat IgA Nephropathy, a Rare and Life-Threatening Kidney Disease
3. BioMarin to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
4. BioMarin to Present at the BioCentury NewsMakers Conference
5. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
6. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
7. Lentigen Appoints Tim Ravenscroft as Chief Executive Officer
8. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
9. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
10. Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management
11. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... According to Ross Selinger, President of Selinger ... the national office market continues to be strong, driven by ... by the third quarter’s surprising 3.9% GDP, unemployment decreasing to ... have held inflation down and the Fed is keeping interest ... remaining soft. , This solid economic news is having a ...
(Date:12/24/2014)... 23, 2014 Pipette.com announces their ... followers can submit their #HolidayInTheLab pictures for a chance ... mates. , For those struggling to think of a ... Holiday in the Lab Contest provides the ideal holiday ... to send pictures of their chemistree, holiday sweaters, ...
(Date:12/24/2014)... 2014 Sigma-Aldrich Corporation (NASDAQ: ... under the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) ... 22, 2014, thereby completing the U.S. HSR Act ... of the Company by Merck KGaA, Darmstadt, Germany.  ... condition to closing the transaction, which remains subject ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... , - German Chemical Parks ... The number of employees in German chemical parks ... In this same period, the number of,companies doing business at ... today by Dr. Klaus-Dieter Juszak, Chairman of the,German Sector Group ...
... EXPANSION INTO EUROPE AND STRENGTHENS ITS SENIOR MANAGEMENT ... 12 OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB), ... for clinical trials, today announced that it has strengthened ... of Dr. Wolfgang Summa. As Executive Vice President, Europe ...
... today that it has acquired from biotechnology company Antisoma ... film-coated tablets), an oral B-cell chronic lymphocytic leukemia (CLL) ... United States for use as a second-line therapy to ... pleased to add Oforta to our existing oncology portfolio, ...
Cached Biology Technology:10,000 New Jobs, Investments Increased 210,000 New Jobs, Investments Increased 3OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 2OmniComm Systems Appoints EDC Veteran Dr. Wolfgang Summa to Executive Vice President, Europe & Asia/Pacific 3Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment 2Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment 3
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
(Date:11/21/2014)... 19, 2014  Earlier this year Donald Spector ... and one of the most prolific inventors in the ... transmitted from Smartphones to third party agencies. Spector envisioned ... one of the earliest known patents in this area. ... the military, child care, elder care and hospital applications. ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... -- Today, oxygen takes up a hefty portion of Earth,s ... air we breathe. However, very early in Earth,s history, O2 ... in the turbulent mix of primordial gases. It wasn,t until ... when oxygen made any measurable dent in the atmosphere, stimulating ...
... salt for all seasons. It turns up not only in ... coral reefs and even in pearls. The compound exists ... it is not clear what determines which variant an organism ... A team of researchers led by LMU geobiologist Dr. Azizur ...
... at risk for a certain form of colon and other ... surviving or even avoiding the diseases, thanks to a new ... Hospital. The Intermountain Heathcare group of scientists used sophisticated ... identify patients who may have Lynch syndrome, an inherited cancer ...
Cached Biology News:MIT: Oxygen's watery past 2MIT: Oxygen's watery past 3New process that may save lives of cancer patients is effective and significantly less costly 2New process that may save lives of cancer patients is effective and significantly less costly 3
RAT ANTI RAT RT1Au (CLASS I POLYMORPHIC) Immunogen: AO lymphoid cells...
Human VEGF R Phycoerythrin Sampler (Cl 89106, 49560, 54733)...
MOUSE ANTI SIMIAN VIRUS 5:FITC Immunogen: Simian virus 5...
Collected from normal, healthy animals in carefully maintained standing herds of US orgin. Pricing: $45/unit for 1 - 10 units...
Biology Products: